STAAR Surgical (NASDAQ:STAA)’s stock price traded down 6% during trading on Thursday . The company traded as low as $30.56 and last traded at $30.70, 530,272 shares traded hands during trading. An increase of 23% from the average session volume of 430,366 shares. The stock had previously closed at $32.67.
A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday, July 12th. Canaccord Genuity lowered their price target on shares of Jamieson Wellness from C$23.00 to C$20.00 in a report on Monday, May 6th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a report on Wednesday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $42.00.
The business’s fifty day simple moving average is $29.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.41 and a quick ratio of 4.83. The stock has a market cap of $1.42 billion, a P/E ratio of 109.64 and a beta of 2.32.
STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The company had revenue of $32.58 million during the quarter, compared to analyst estimates of $32.40 million. During the same period in the prior year, the business posted $0.01 EPS. On average, equities research analysts predict that STAAR Surgical will post 0.33 earnings per share for the current fiscal year.
In related news, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction on Friday, May 3rd. The shares were acquired at an average cost of $22.23 per share, with a total value of $2,223,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.90% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the business. Mascoma Wealth Management LLC purchased a new position in STAAR Surgical during the 1st quarter valued at $38,000. Aspire Private Capital LLC purchased a new stake in shares of STAAR Surgical in the 1st quarter worth about $51,000. AdvisorNet Financial Inc grew its position in shares of STAAR Surgical by 54.8% in the 2nd quarter. AdvisorNet Financial Inc now owns 1,742 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 617 shares during the period. Lavaca Capital LLC purchased a new stake in shares of STAAR Surgical in the 1st quarter worth about $180,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of STAAR Surgical in the 1st quarter worth about $186,000. 89.80% of the stock is currently owned by institutional investors and hedge funds.
STAAR Surgical Company Profile (NASDAQ:STAA)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.